Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Chondrosarcoma

Eli Lilly and CompanySmall moleculePhase 1/2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Chondrosarcoma cohort.

Asset / SponsorPhaseRating
ag-120
Memorial Sloan Kettering Cancer Center
Phase 2B
Azacitidine
IGM Biosciences, Inc.
Phase 1/2CCC
Angiotensin-(1-7)
Wake Forest University Health Sciences
Phase 2CCC
Atezolizumab
National Cancer Institute (NCI)
Phase 2CCC
Adapt-001
EpicentRx, Inc.
Phase 2CCC

View all 24 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →